Ramipril Capsules USP 5 mg, a) 90 count (NDC 68180-590-09), b) 100 count NDC 68180-590-01), and c) 500 count (NDC 68180-590-02) bottles, Rx only, Manufactured for Lupin Pharmaceuticals, Inc., Baltimore, MD, Manufactured by Lupin Limited, Goa, India
Published November 27, 2024 · Recall initiated: October 23, 2024
Summary
FDA records drug Class II recall D-0053-2025, published November 27, 2024 and initiated October 23, 2024. Recalling firm: Lupin Pharmaceuticals Inc.; Status: Terminated; Reported quantity: 146,322 bottles; Lot: a) NDC 68180-590-09; Lots G326928, exp. date 30-Sep-25, GA00964, exp. date 31-Dec-25, b) NDC 68180-590-01, Lots G326897, G326929, exp. date 30-Sep-25, GA00854, GA00933, GA00954, exp. date 31-Dec-25, c) NDC 68180-590-02, Lot GA00955, exp. date 31-Dec-25. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
CGMP Deviations: Active pharmaceutical ingredient was sourced from an unapproved vendor
What to do
Voluntary: Firm initiated · Letter
Get an email if RAMIPRIL has another recall
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Brand
- RAMIPRIL
- Manufacturer
- Lupin Pharmaceuticals Inc.
- Distributor
- Product was distributed to 30 wholesalers/distributors who may have further distributed the product nationwide.
- UPC
- 0368180591092
- Lot
- a) NDC 68180-590-09; Lots G326928, exp. date 30-Sep-25, GA00964, exp. date 31-Dec-25, b) NDC 68180-590-01, Lots G326897, G326929, exp. date 30-Sep-25, GA00854, GA00933, GA00954, exp. date 31-Dec-25, c) NDC 68180-590-02, Lot GA00955, exp. date 31-Dec-25
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDARamipril Capsules USP, 10 mg, packaged in a) 100 Capsules (NDC 76282-673-01) and b) 500 Capsules (NDCSeptember 2, 2026
- FDARamipril Capsules USP 10 mg, a) 90 count (NDC 68180-591-09), b) 100 count NDC 68180-591-01), and c) 500 countNovember 27, 2024
- FDARamipril Capsules USP 2.5 mg, a) 90 count (NDC 68180-589-09), b) 100 count NDC 68180-589-01), and c) 500 countNovember 27, 2024
- FDABEVACIZUMAB (AVASTIN)1.25mg/0.05mL, Sterile Injection, 0.5 mL Single-Dose Syringe, Rx Only, Repackaged by:November 27, 2024
- FDAXelstrym (dextroamphetamine) transdermal system, 13.5 mg dextroamphetamine/9 hours, 30 individually sealedNovember 27, 2024
- FDAGuaifenesin Dextromethorphan Syrup, 100 mg/10mg per 5 mL, Major Pharmaceuticals 8401 Bearing Drive, Suite 100,November 27, 2024
Questions about this recall
Was Ramipril Capsules USP 5 mg, a) 90 count (NDC 68180-590-09), b) 100 count NDC 68180-590-01), and c) 500 count (NDC 68180-590-02) bottles, Rx only, Manufactured for Lupin Pharmaceuticals, Inc., Baltimore, MD, Manufactured by Lupin Limited, Goa, India recalled?
Yes. FDA published recall D-0053-2025 on November 27, 2024. Reported hazard: CGMP Deviations: Active pharmaceutical ingredient was sourced from an unapproved vendor
What should I do if I have this product?
Voluntary: Firm initiated · Letter
How do I know if my unit is part of the recall?
Compare your product details with the notice. Brand: RAMIPRIL. UPC: 0368180591092.